Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

Founder Of The Royal Pharmaceutical Society Commemorated In Tunbridge Wells
The 150th anniversary of the death of Jacob Bell, founder of the Royal Pharmaceutical Society of Great Britain, was remembered on Friday 12 June at a ceremony at his memorial in Woodbury Park Cemetery, Royal Tunbridge Wells.
generic viagra online
Injection Reverses Heart-Attack Damage
Injured heart tissue normally can"t regrow, but researchers at Children"s Hospital Boston have now laid the groundwork for regenerating heart tissue after a heart attack, in patients with heart failure, or in children with congenital heart defects. In the July 24 issue of Cell, they show that a growth factor called neuregulin1 (NRG1), which is involved in the initial development of the heart and nervous system, can spur heart-muscle growth and recovery of cardiac function when injected systemically into animals after a heart attack.
News of the day
Sites Continue To Expand Their Capabilities With Digisonics
HeartCare Cardiovascular Specialists in Libertyville, IL has expanded their CVIS capabilities with a new DigiNet Pro system. This system will provide the site with web access enabling users to have full CVIS capability from anywhere at anytime.
Medical Devices

St. Joseph's Selected As Only Site To Provide New Genetic Test For Deadly Type Of Brain Cancer

St. Joseph"s Hospital and Medical Center in Phoenix has partnered with Castle Biosciences, Inc. to provide the nation"s first genomics-based test for patients suffering from glioblastoma multiforme, the most deadly form of primary brain cancer. This new test is used to help doctors and patients consider various treatment options. Castle Biosciences chose St. Joseph"s DNA Diagnostics Lab as the sole location to perform this test following an extensive review process. The Greater Phoenix Economic Council facilitated key connections that led to the agreement between St. Joseph"s and Castle Biosciences. Physicians from across the United States have now begun sending cases to Castle for DecisionDx-GBM testing to be run in St. Joseph"s DNA Diagnostics Lab. Based on a tumor"s expression of a certain set of genes, this molecular diagnostic test can tell a doctor if the tumor is likely to be sensitive or resistant to the standard first line treatment. If resistant, precious time might be saved by evaluating different treatment plan options. "Based on the results of clinical studies, DecisionDx-GBM is the most sensitive test available to tell a patient the likelihood of survival with first line therapy," says Derek Maetzold, president and CEO of Castle Biosciences. "The test results aid patients and physicians with their treatment planning and other decisions." Dr. John Stone heads the DNA Diagnostics Laboratory at St. Joseph"s and says his lab is "making possible personalized medicine, based on genomics. Our offering this test is a prime example of translational genomics closing the loop between the research lab and the clinic." Dr. Stone believes the testing can "make a real difference in people"s lives. While there is currently no cure, this test can certainly help patients understand and plan for the likely course of the disease." Lynne Reaves St. Joseph"s Hospital and Medical Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009